Abcuro
Clinical-stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells.
Notes
Abcuro is a clinical-stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company's lead program is ulviprubart (ABC008), a first-in-class anti-KLRG1 antibody currently in Phase 2/3 clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL).
Abcuro raised $200 million in Series C financing in February 2025, led by NEA with participation from Foresite Capital and existing investors. The company previously raised $155 million in Series B financing in August 2023.
Team
- Alex Martin - Chief Executive Officer
- H. Jeffrey Wilkins, M.D. - Chief Medical Officer
- George Eldridge - Chief Financial Officer
- Courtney Cupples - Chief Commercial Officer
- Mark Pruzanski, M.D. - Chairman of the Board
Additional Research Findings
- Lead drug candidate ulviprubart (ABC008) targets KLRG1 for selective depletion of cytotoxic T cells
- Completed enrollment of registrational Phase 2/3 MUSCLE trial for inclusion body myositis
- Expected to report initial Phase 2/3 data in first half of 2026
- FDA Orphan Drug Designation for ABC008 in IBM
- Headquarters: 55 Chapel Street, Suite 200, Newton, MA 02458
- In Bain Capital Life Sciences portfolio